微创手术联合溶栓治疗脑出血清除的贝叶斯再分析:一项随机对照试验的探索性分析
该研究对MISTIE-3试验进行贝叶斯再分析,评估微创手术联合溶栓(MISTIE干预)对脑出血患者365天良好功能结局(mRS 0-3)和死亡率的潜在效应概率。结果显示,在不同先验分布下,MISTIE干预对365天mRS有任何获益(RR>1)的概率为68%-87%,但对RR>1.10的概率≤55%,对RR>1.52的概率为0%。对365天死亡率RR<1的概率为93%。研究结论认为,贝叶斯分析未改变基于频率学派的解释,但直接估计了治疗效应的概率。
要点
- MISTIE干预对365天良好功能结局(mRS 0-3)有任何获益(RR>1)的贝叶斯概率为68%-87%,但效应量大于10%的概率≤55%。
- MISTIE干预对365天死亡率RR<1的概率为93%,对180天和30天死亡率RR<1的概率分别为98%和99%。
- 证据等级为Class II,表明MISTIE干预未显著改善功能结局,但研究精度不足以排除潜在获益。
核心结论
- 在多种先验分布下,MISTIE干预对脑出血患者365天mRS有任何获益的贝叶斯概率介于68%至87%之间。
- 这些分析未改变基于频率学派的试验解释,但贝叶斯框架直接估计了潜在治疗效应的概率。
研究设计与样本
- MISTIE-3是一项多中心3期随机对照试验,评估MISTIE干预的有效性和安全性。
- 共纳入506例成人(18岁及以上)自发性、非创伤性、幕上脑出血且出血量≥30 mL的患者,随机接受MISTIE干预(n=255)或标准内科治疗(n=251)。
- 本研究为对MISTIE-3试验的探索性事后贝叶斯再分析,使用参考先验(包括最小信息、热情、怀疑先验)和数据衍生先验(分层随机效应模型)。
主要发现
- MISTIE干预对365天良好mRS(0-3分)有任何获益(RR>1)的概率:最小信息先验70%,热情先验87%,怀疑先验68%,数据衍生先验73%。
- 对于RR>1.10,上述概率在所有先验下均≤55%;对于RR>1.52,概率为0%。
- MISTIE干预对180天和30天mRS有任何获益(RR>1)的概率分别为65%和80%。
- MISTIE干预对365天、180天和30天死亡率RR<1的概率分别为93%、98%和99%。
关键数值与推荐
- 证据等级:Class II,表明微创手术(MIS)联合重组组织型纤溶酶原激活剂(rt-PA)未显著改善脑出血患者的功能结局,但研究精度不足以排除潜在获益。
临床怎么用
- 原文未据此给出推荐。
局限性
- 本研究为探索性事后贝叶斯再分析。
- 研究精度不足以排除MIS+rt-PA的潜在获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Bayesian analysis of randomized controlled trials (RCTs) can extend the value of trial data beyond interpretations based on conventional p value-based binary cutoffs. We conducted an exploratory post hoc Bayesian reanalysis of the minimally invasive surgery with thrombolysis for intracerebral hemorrhage (ICH) evacuation (MISTIE-3) trial and derived probabilities of potential intervention effect on functional and survival outcomes. METHODS: MISTIE-3 was a multicenter phase 3 RCT designed to evaluate the efficacy and safety of the MISTIE intervention. Five hundred and six adults (18 years or older) with spontaneous, nontraumatic, supratentorial ICH of ≥30 mL were randomized to receive either the MISTIE intervention (n = 255) or standard medical care (n = 251). We provide Bayesian-derived estimates of the effect of the MISTIE intervention on achieving a good 365-day modified Rankin Scale score (mRS score 0-3) as relative risk (RR) and absolute risk difference (ARD), and the probabilities that these treatment effects are greater than prespecified thresholds. We used 2 sets of prior distributions: (1) reference priors, including minimally informative, enthusiastic, and skeptical priors, and (2) data-derived prior distribution, using a hierarchical random effects model. We additionally evaluated the potential effects of the MISTIE intervention on 180-day and 30-day mRS and 365-, 180-, and 30-day mortality using data-derived priors. RESULTS: The Bayesian-derived probability that MISTIE intervention has any beneficial effect (RR >1) on achieving a good 365-day mRS score was 70% using minimally informative prior, 87% with enthusiastic prior, 68% with skeptical prior, and 73% with data-derived prior. However, these probabilities were ≤55% for RR >1.10 and 0% for RR >1.52 across a range of priors. The probabilities of achieving RR >1 for 180- and 30-day mRS scores are 65% and 80%, respectively. Furthermore, the probabilities of achieving RR <1 for 365-, 180-, and 30-day mortality are 93%, 98%, and 99%, respectively. DISCUSSION: Our exploratory analyses indicate that across a range of priors, the Bayesian-derived probability of MISTIE intervention having any beneficial effect on 365-day mRS for patients with ICH is between 68% and 87%. These analyses do not change the frequentist-based interpretation of the trial. However, unlike the frequentist p values, which indirectly evaluate treatment effects and only provide an arbitrary binary cutoff (such as 0.05), the Bayesian framework directly estimates the probabilities of potential treatment effects. TRIAL REGISTRATION INFORMATION: ClinicalTrials.gov/ct2/show/NCT01827046. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that minimally invasive surgery (MIS) + recombinant tissue plasminogen activator (rt-PA) does not significantly improve functional outcome in patients with ICH. However, this study lacks the precision to exclude a potential benefit of MIS + rt-PA.
引用
- Bako AT, Potter T, Pan AP, et al. Minimally Invasive Surgery With Thrombolysis for Intracerebral Hemorrhage Evacuation: Bayesian Reanalysis of a Randomized Controlled Trial. Neurology. 2023. PMID: 37684058. doi:10.1212/WNL.0000000000207735
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。